KDR and neoplasm: For instance, Apatinib’s marked efficacy in improving DCR likely stems from its selective and potent VEGFR-2 inhibition, significantly suppressing tumor angiogenesis and thereby stabilizing disease rather than achieving rapid tumor regression (Gao et al., 2019; Liao et al., 2019).